Other News To Note
Wednesday, May 4, 2011
AtheroNova Inc., of Irvine, Calif., will pursue an additional indication to address unmet needs in stroke prevention with a compound to treat intracranial atherosclerosis disease, regarded as a primary cause of ischemic stroke. AtheroNova is conducting two second-round preclinical studies evaluating the atherosclerotic plaque regression efficacy of the company's compounds.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.